Specialties
Board Certification
|
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Infectious Disease)
|
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Assistant Professor |
|---|---|
| Academic Divisions |
Infectious Diseases
|
| Board Certification |
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Infectious Disease)
|
Education history
| Undergraduate | Biomedical Sciences - Auburn University | B.S. |
|---|---|---|
| Professional Medical | Medicine - University of South Alabama College of Medicine | M.D. |
| Residency | Internal Medicine - University of Chicago Medicine at NorthShore | Resident |
| Residency | Internal Medicine - University of Chicago Medicine at NorthShore | Chief Resident |
| Fellowship | Infectious Disease - Loyola University Medical Center | Fellow |
| Fellowship | Infectious Disease Research - Loyola University Medical Center | Fellow |
Selected Publications
Journal Article
- Skinner AM, Guh AY, Petrella LA, Sambol S, Cheknis A, Johnson S, Czaja CA, Johnston H, Basiliere E, Dhonau RA, Korhonen L, Paulick AL, Samore MH, Adamczyk M, Gargis AS, Gerding D (2026). Clostridioides difficile clinical diagnostic test methods and results are associated with recovery of C. difficile by stool culture. Microbiology spectrum, e0340825.
- Barash JR, Sambol SP, Skinner AM, Johnson S, Gerding D (2026). Clostridioides difficile colonization of Twin Patients Recovering From Infant Botulism. Anaerobe, 97, 103022.
- Skinner AM, Young Kim D, Cheknis A, Lin M, Hayden MK, Moore NM, Harrington A, Tesic V, Beavis KG, Gerding DN, Kociolek LK, Evans CT, Johnson (2026). Molecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers. Antimicrobial stewardship & healthcare epidemiology, 6(1), e64.
- Skinner AM, Lodise TP, Reilly J, Guthmueller B, Srivastava S, Axelrad J (2026). Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS. Infectious diseases and therapy, 15(3), 889-901.
- Wang MS, Zimmerman G, Klein T, Stibbe B, Rykse M, Ballard S, Vijayam N, Brown J, Raza K, Beckman S, Skinner A (2025). Three stages of laboratory stewardship in improving appropriate Clostridioides difficile testing in a community-based setting. Antimicrobial stewardship & healthcare epidemiology, 5(1), e81.
- Redmond SN, Cadnum JL, Jencson AL, Kaple CE, Wilson BM, Skinner AM, Gargis AS, Hwang M, Choi H, Chatterjee P, Jinadatha C, Donskey C (2025). Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital. Clinical infectious diseases, 80(5), 984-991.
- Drwiega EN, Johnson S, Danziger LH, Skinner A (2024). Risk of rehospitalization due to Clostridioides difficile infection among hospitalized patients with Clostridioides difficile: a cohort study. Infection control and hospital epidemiology, 1-7.
- Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, Coffey KC, Durkin M, Gonzales-Luna AJ, Guh AY, Kwon JH, Martin E, Mehrotra P, Polage CR, Pulia MS, Rock C, Skinner AM, Vaughn VM, Vijayan T, Yarrington ME, Morgan DJ, CDC Prevention Epicenters Progra (2024). Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure. Antimicrobial stewardship & healthcare epidemiology, 4(1), e168.
- Reveles KR, Gonzales-Luna AJ, Golan Y, Alonso CD, Guthmueller B, Tan X, Bidell MR, Pokhilko V, Crawford CV, Skinner A (2024). Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study. Open forum infectious diseases, 11(7), ofae341.
- Hunt A, Danziger LH, Johnson S, Skinner A (2024). Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection. Open forum infectious diseases, 11(4), ofae153.
- Wieczorkiewicz JT, Skinner AM, Cheknis A, Petrella LA, Stevens VW, Wright LM, Gerding DN, Johnson (2024). Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures. Antimicrobial agents and chemotherapy, 68(8), e0069824.
- Chang LL, Allegretti J, Skinner AM, Dubberke E (2023). Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection. The New England journal of medicine, 388(7), 654-656.
- Skinner AM, Petrella LA, Cheknis A, Johnson (2023). Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials. The Journal of antimicrobial chemotherapy,
- Sambol SP, Skinner AM, Serna-Perez F, Owen B, Gerding DN, Johnson (2023). Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin. Microbiology spectrum, 11(2), e0051723.
- van Prehn J, van Werkhoven CH, Skinner AM, Guery B, Dubberke ER, Kuijper E (2023). Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence. Clinical microbiology and infection,
- Skinner AM, Tan X, Westman C, Birris T, Drwiega E, Wang MS, Johnson (2023). Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI. Anaerobe, 102788.
- Crone AS, Wright LM, Cheknis A, Johnson S, Pacheco SM, Skinner A (2023). Characteristics and outcomes of Clostridioides difficile infection after a change in the diagnostic testing algorithm. Infection control and hospital epidemiology, 1-6.
- Wright LM, Skinner AM, Cheknis A, McBurney C, Ge L, Pacheco SM, Leehey D, Gerding DN, Johnson (2023). Effect of the COVID-19 Pandemic on Rates and Epidemiology of Clostridioides difficile Infection in One VA Hospital. Antibiotics (Basel, Switzerland), 12(7),
- Feuerstadt P, Crawford CV, Tan X, Pokhilko V, Bancke L, Ng S, Guthmueller B, Bidell MR, Tillotson G, Johnson S, Skinner A (2023). Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection: Subgroup Analysis of PUNCH CD2 and PUNCH CD3. Journal of clinical gastroenterology,
- Skinner AM, Petrella L, Spandoni S, Serna-Perez F, Johnson (2022). Can Clostridium innocuum Masquerade as Clostridioides difficile?. Clinical infectious diseases, 75(7), 1268-1269.
- Skinner AM, Tan X, Sirbu BD, Danziger LH, Gerding DN, Johnson (2021). A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences. Clinical infectious diseases, 73(6), 1107-1109.
- Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox M (2021). Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical infectious diseases, 73(5), e1029-e1044.
- Skinner AM, Petrella L, Siddiqui F, Sambol SP, Gulvik CA, Gerding DN, Donskey CJ, Johnson (2020). Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain. Emerging infectious diseases, 26(2), 247-254.
- Skinner AM, Yu B, Cheknis A, Pacheco SM, Gerding DN, Johnson (2020). Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity. Infection control and hospital epidemiology, 41(10), 1148-1153.
- Skinner AM, Scardina T, Kociolek L (2020). Fidaxomicin for the treatment of Clostridioides difficile in children. Future microbiology, 15(11), 967-979.
- Skinner AM, Phillips ST, Merrigan MM, O'Leary KJ, Sambol SP, Siddiqui F, Peterson LR, Gerding DN, Johnson (2020). The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile. Journal of clinical medicine, 10(1),
- Peterson LR, Samia NI, Skinner AM, Chopra A, Smith B (2017). Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus. Open Forum Infect Dis, 4(2), ofx093.
Review
- Johnson S, Skinner AM, Lostutter C, Duke T, Posthaus (2025). Enteritis necroticans and Clostridium perfringens type C; Epidemiological and pathological findings over the past 20 years. PLoS neglected tropical diseases, 19(2), e0012836.
- Gonzales-Luna AJ, Skinner AM, Alonso CD, Bouza E, Cornely OA, de Meij TGJ, Drew RJ, Garey KW, Gerding DN, Johnson S, Kahn SA, Kato H, Kelly CP, Kelly CR, Kociolek LK, Kuijper EJ, Louie T, Riley TV, Sandora TJ, Vehreschild MJGT, Wilcox MH, Dubberke ER, EXPAND Cdiff grou (2023). Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. The Lancet. Infectious diseases,
Book Chapter
- Suk M, Skinner AM, Mahajan S, Franklin C (2018). Judicial Involvement in End-of-LifeDecisions and Informed Consent. In Yu M, Gabrielli A, Wood KE, Layon AJ (Eds.), Civetta, Taylor, & Kirby's Critical Care Medicine (5th Edition, pp. 21-32). Philadelphia, PA: Lippincott Williams & Wilkins.
Letter
- van Prehn J, Skinner AM, Krutova M, Guery (2024). Re: 'The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes' by Stabholz et al. Clinical microbiology and infection, 30(2), 261-262.
- van Prehn J, Skinner A, Krutova M, Guery (2023). Re: 'the effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes' by Stabholz et al. Clinical microbiology and infection, 30(2), 261-262.